Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

It is said that every newborn faces a potential risk until the baby has been screened for <keyword id="1144427" type="UNKNOWN" weightage="100" keywordseo="medical-conditions">medical conditions</keyword>. A <keyword id="2024251" type="UNKNOWN" weightage="100" keywordseo="Genetic-screening">genetic screening</keyword> of the newborn means enhanced <keyword id="2024262" type="UNKNOWN" weightage="100" keywordseo="Biotechnological-capacity">biotechnological capacity</keyword>, which ensures fast, accurate and expanded testing going beyond routine disorders. <keyword id="2024252" type="UNKNOWN" weightage="100" keywordseo="Newborn-screening">Newborn screening</keyword> (<keyword id="116258" type="ORGANIZATION" weightage="100" keywordseo="NBS">NBS</keyword>) has been made compulsory in 52 countries across the world, bringing down <keyword id="153995" type="UNKNOWN" weightage="100" keywordseo="infant-mortality">infant mortality</keyword> and disabilities in children. 
 Simply put, newborn screening (NBS) programme includes testing every newborn soon after its birth, to identify serious or life-threatening conditions which may lead to mental/physical retardation or even early death. The affected baby looks healthy at birth as there is no external defect and these disorders cannot be diagnosed until specifically tested for. However, India is yet to implement a <keyword id="2024264" type="UNKNOWN" weightage="100" keywordseo="National-newborn-screening-programme">national newborn screening programme</keyword> even though 5-15% of newborns fall prey to <keyword id="120871" type="UNKNOWN" weightage="100" keywordseo="Metabolic-disorders">metabolic disorders</keyword>. 
 Understandably, not too many Indian start-ups operate in the NBS space and the <keyword id="49685" type="UNKNOWN" weightage="100" keywordseo="Genetic">genetic</keyword> screening of newborns is rarely done in the country at a macro level. But here is one Mumbai-based start-up that has doing it for over a year now. <keyword id="2024246" type="UNKNOWN" weightage="100" keywordseo="Navigene">Navigene</keyword> has developed a unique and <keyword id="2024273" type="UNKNOWN" weightage="100" keywordseo="Non-invasive-preventive-genetic-screening">non-invasive preventive genetic screening</keyword> service for newborns and adults, which can be implemented at a mass scale. Its primary focus is <keyword id="2024274" type="UNKNOWN" weightage="100" keywordseo="Non-invasive-preventive-testing">non-invasive preventive testing</keyword> including <keyword id="2024278" type="UNKNOWN" weightage="100" keywordseo="Newborn-genetic-screening">newborn genetic screening</keyword>, <keyword id="2024275" type="UNKNOWN" weightage="100" keywordseo="Metabolic-fingerprinting">metabolic fingerprinting</keyword>, <keyword id="2024279" type="UNKNOWN" weightage="100" keywordseo="Prenatal-screening">prenatal screening</keyword> and more, besides offering <keyword id="2024280" type="UNKNOWN" weightage="100" keywordseo="Diagnostic-testing">diagnostic testing</keyword> (<keyword id="2024281" type="UNKNOWN" weightage="100" keywordseo="Cytogenetics">cytogenetics</keyword> &amp; <keyword id="1284857" type="ORGANIZATION" weightage="100" keywordseo="Molecular-Genetics">molecular genetics</keyword>). <keyword id="2024283" type="UNKNOWN" weightage="100" keywordseo="Navigene-Baby-Screen">Navigene Baby Screen</keyword>, the start-up’s flagship product, screens the newborns for 110 genetic and metabolic disorders on the very 3rd day after birth and the company claims it is one of the most comprehensive screening tests in the world. Here is a snapshot that captures the start-up’s operations, vision and viability. 
 
Who runs Navigene (navigene.in): Two co-founders – Dr <keyword id="2024250" type="UNKNOWN" weightage="100" keywordseo="Rishi-Dixit">Rishi Dixit</keyword> (MD &amp; CEO) and Dr <keyword id="1888201" type="PERSON" weightage="100" keywordseo="Vrushali-Joshi">Vrushali Joshi</keyword> (CTO) – and the early-stage incubation and <keyword id="6357097" type="COMPANY" weightage="80" keywordseo="venture-capital">venture capital</keyword> firm, <keyword id="720080" type="COMPANY" weightage="100" keywordseo="IncuCapital">IncuCapital</keyword>. An MBBS and MBA, Dr Rishi has a deep understanding of the healthcare marketing space and also worked with start-ups. Before starting Navigene, he was head of sales &amp; strategy at a start-up in the similar domain. Prior to that, he was manager, health analytics, with ICICI Prudential Life insurance. Dr Vrushali holds a Ph.D. from Mumbai University and is a leading geneticist with more that 15 years of experience. She is also a government-certified genetic counsellor. 
 Navigene was set up by the two co-founders in April 2012, along with IncuCapital’s senior venture partners’ team of <keyword id="2024248" type="UNKNOWN" weightage="100" keywordseo="Surojit-Nandy">Surojit Nandy</keyword>, <keyword id="6393254" type="PERSON" weightage="100" keywordseo="Manish-Kumar">Manish Kumar</keyword> and <keyword id="2024247" type="UNKNOWN" weightage="100" keywordseo="Prashant-Maharaj">Prashant Maharaj</keyword>. The company started operations in November that year. Currently, it boasts a state-of-the-art testing facility and central lab in Mumbai where all samples are flown in from different parts of the country and also from global destinations. This facility also serves as the head office while 2-3 sales people are assigned to each location. Weekly sales meetings are generally held at local CCDs – a good example of asset-light sales offices. 
 But going forward, the start-up plans to open sales offices in Delhi, Bangalore and Hyderabad – small facilities for operational and logistics management. As sample collection is generally done by the people themselves or the <keyword id="6355907" type="UNKNOWN" weightage="100" keywordseo="Medical-facilities">medical facilities</keyword>, the Navigene staff simply picks them up from homes/hospitals and courier them to the HO in Mumbai. 
 
What inspired the venture: The knowledge that non-traditional, highly accurate and revolutionary ways of medical diagnosis is possible through genetic screening and diagnostic techniques. Navigene was founded to bring these advanced <keyword id="684042" type="TECHNOLOGY" weightage="100" keywordseo="medical-technologies">medical technologies</keyword> to India. 
 
What’s the pitch: Early and accurate prediction/diagnosis of disorders and ailments in newborns and adults, through <keyword id="2024271" type="UNKNOWN" weightage="100" keywordseo="Preventive-genetic-screening">preventive genetic screening</keyword> – so that every individual has the opportunity to manage his/her health. “Over the years, we have learnt a great deal about how genes function and how they can cause certain problems. Now is the time to use that knowledge in exciting new ways to prevent and treat <keyword id="6377700" type="UNKNOWN" weightage="100" keywordseo="health-problems">health problems</keyword>,” says Dr Rishi. 
 
How it works: Navigene currently caters to the B2B segment – <keyword id="796241" type="UNKNOWN" weightage="100" keywordseo="corporate-hospitals">corporate hospitals</keyword>, high-end nursing homes with birthing facilities, NICUs (<keyword id="1145483" type="UNKNOWN" weightage="100" keywordseo="neonatal-intensive-care-units">neonatal intensive care units</keyword>) and state-of-the-art <keyword id="2024290" type="UNKNOWN" weightage="100" keywordseo="Paediatric-facilities">paediatric facilities</keyword>. It also works with individual obstetricians/gynaecologists and paediatricians. The start-up typically approaches medical facilities who, in turn, offer/recommend these services to their clients. Once a client registers for the tests, he/she is given the sample collection kit and the rest of the testing procedure follows. 
 
As for newborn screening, parents get the kit as soon as they register and after the birth of the baby, either the hospital staff or the parents collect the urine sample of the baby on the 3rd day. It is then sent Navigene’s central lab in Mumbai where the sample is analysed and reports are sent within 4 days. If the report detects any abnormality, the concerned doctor/hospital/parents are immediately informed and further consultation could be arranged with medical experts. Genetic counselling for the parents is also offered in such cases. 
 
Show me the money: As of now, the start-up has a B2B revenue model in place while the B2C space is essentially serviced through its partners who can reach out to more people. Navigene charges fee per sample testing and its flagship solution, Navigene Baby Screen (NBS), which tests urine sample for 110 disorders, costs Rs 5,000. But to make it more affordable for Tier II cities and smaller medical facilities, customised packages start from Rs 900 for tracking 3-4 basic disorders and can go up to Rs 2,700 for screening 31 commonest disorders that affect infants in the first few months. The company has also tied up with a leading stem cell company for instant access to a large B2C market. “Plus, we want to work with the state governments when they start running the NBS programme at the state-run hospitals, but we will keep the packages small,” says Dr Rishi. 
 
The market size is also huge as around 30 million babies are born in India every year. “As of now, we are targeting 40 cities in India where our addressable market (a fraction of the urban population in these cities) is around 30 lakh babies a year. We aim to cover most of them over the next 3 years through our proprietary sales channel,” adds Dr Rishi. 
 
Claim to fame: A value driver in a critical industry while expansion is its forte. Navigene is a pioneer of sorts, bringing crucial preventive health screening for newborn babies at an affordable price. The start-up is currently doing 500 samples a month and targeting 10,000 samples in the next 3 years. 
 Navigene raised an undisclosed seed round with the help of its institutional co-promoter IncuCapital in August 2012 and it will be raising Series A <keyword id="6357455" type="EVENT" weightage="100" keywordseo="Funding">funding</keyword> in the next 2-3 months. The money will be utilised to grow its presence pan-India and also in other geographies such as South-east Asia and <keyword id="48890" type="COUNTRY" weightage="80" keywordseo="Latin-America">Latin America</keyword>. “We can’t disclose the names just now, but these would be all bigger and more developed countries. We are also talking to a few players in Latin America, which can lead to substantial global expansion,” says Surojit Nandy of IncuCapital. As for pan-India expansion, the company plans to reach 40 cities in next the 3 years through its own B2B sales force. 
 The start-up has hit <keyword id="2024302" type="UNKNOWN" weightage="100" keywordseo="Operational-breakeven">operational breakeven</keyword> in December 2013, within 11 months from starting its sales operations. But it is not really looking at that as a landmark. “We don’t intend to remain operationally cash-positive as we are growing at a breakneck speed and want to keep investing in the growth. That’s the reason we are looking at the Series A funding soon,” says Dr Rishi. 
 “We are also working on some breakthrough <keyword id="2024304" type="UNKNOWN" weightage="100" keywordseo="Screening-products">screening products</keyword> around <keyword id="350054" type="TECHNOLOGY" weightage="100" keywordseo="metabolomics">metabolomics</keyword> in areas like oral &amp; <keyword id="16070" type="ORGANIZATION" weightage="80" keywordseo="breast-cancer">breast cancer</keyword>, and adult metabolic disorders. So a big chunk of the Series A money will be used for product development. We will <keyword id="47916" type="UNKNOWN" weightage="80" keywordseo="invest">invest</keyword> a good amount in Capex and Opex to further strengthen our testing portfolio,” he adds. 
 
Biggest challenge: According to Dr Rishi, there’s no real competition here as very few companies in India focus on genetics (metabolomics). As for the newborn screening business, a few labs who do screening through blood sample testing could be competitors, but they use an entirely different technology platform and can track a maximum of 45 disorders. However, creating awareness among prospective clients is currently the biggest challenge. <keyword id="1912844" type="UNKNOWN" weightage="100" keywordseo="patient-education">Patient education</keyword> is virtually non-existent in India while the cost of reaching them at a micro level could be huge. “That’s why we are opting for online registrations, which will reduce operational costs,” he notes. “Then there are other screening products we are working on. When they hit the market, we should be way ahead of others,” concludes Dr Rishi.

This Start-up Provides Genetic Screening For
Newborns, Adults; To Raise Series A Funding In 2-3 Months

<ul class="summary-list"><li>More than five dozen people reported seeking medical attention after consuming Diamond Shruumz products.</li><li>A study also found some of the company's gummies contained psilocin, a controlled substance.</li></ul>Diamond Shruumz, the company whose <a target="_blank" class="editor-rtfLink" href="https://www.businessinsider.com/microdosing-chocolate-bar-diamond-shruumz-illness-hospital-2024-6">microdosing chocolate bars</a> prompted a <a target="_blank" class="" href="https://www.fda.gov/food/outbreaks-foodborne-illness/investigation-illnesses-diamond-shruumz-brand-chocolate-bars-cones-gummies-june-2024">Food and Drug Administration investigation</a> in June, has also sold gummies made with an illegal substance, according to a new report from the <a target="_blank" class="" href="https://www.cdc.gov/mmwr/volumes/73/wr/mm7328a3.htm#T1_down">Centers for Disease Control and Prevention</a>.The FDA first alerted the public about Diamond Shruumz products after eight people in four states fell ill from consuming the retailer's microdosing chocolate bars.As of July 15, the FDA said, those numbers had ballooned to 69 illnesses across 28 states."Sixty (60) of the 69 people have reported seeking medical care, 36 have been hospitalized, and there is one potentially associated death under investigation," the FDA said.<a target="_blank" class="editor-rtfLink" href="https://www.businessinsider.com/microdosing-psilocybin-mushrooms-for-creativity-startups-2024-3">Microdosing</a> is the practice of taking small doses of a drug, typically psychedelics such as psilocybin, to improve creativity and mental health. Microdosing has become trendy in Silicon Valley, <a target="_blank" class="" href="https://www.businessinsider.com/microdose-magic-mushrooms-increase-productivity-at-work-2024-5">even among CEOs</a>.Diamond Shruumz's website said its products didn't contain psilocybin or any other scheduled drugs.But tests conducted by the University of Virginia Health Toxicology Laboratory found psilocin in Diamond Shruumz's Sour Peach Apple and Rainbow gummies.Psilocin is a "psychedelic mushroom alkaloid," according to <a target="_blank" class="" href="http://www.t3db.ca/toxins/T3D2458">The Metabolomics Innovation Centre</a>. The Drug Enforcement Administration considers psilocin a Schedule I controlled substance in some states, including Virginia, where the study was conducted.The CDC study says five people underwent hospital evaluations from September to June after eating gummies labeled to contain Amanita muscaria.Although Amanita muscaria can sometimes cause undesired symptoms, the report says it's legal."Persons who purchase products advertised as psychedelic or nootropic mushroom gummies should be aware that package labels might not accurately represent the contents and that these products could contain substances that might produce unexpected and potentially toxic effects," the report says.Representatives for Diamond Shruumz and the University of Virginia Health Toxicology Laboratory didn't respond to a request for comment from Business Insider.Diamond Shruumz recalled all of its products — including its gummies and chocolate bars — in June after illnesses continued to rise across the country.The FDA said it would monitor Prophet Premium Blends, the company behind Diamond Shruumz, during its recall."Consumers should not purchase or consume any Diamond Shruumz-brand products," the agency added.

Dozens of illnesses across 28 states are now linked to a company's 'microdosing' gummies and chocolate bars

<ul class="summary-list"><li>Shares of <keyword id="10701757" type="UNKNOWN" weightage="60" keywordseo="tyme-technologies">Tyme Technologies</keyword> soared as much as 127% on Wednesday.</li><li>The company was granted additional patent claims for its product TYME-19 which can be used to treat <keyword id="8763838" type="UNKNOWN" weightage="60" keywordseo="covid-19">COVID-19</keyword>.</li><li>"We believe that TYME-19 diminishes the ability of COVID-19 to hijack an infected cell," the company wrote in a statement.</li></ul><a href="https://markets.businessinsider.com/stocks/tyme-stock">Tyme Technologies</a> skyrocketed as much as 127% on Wednesday after the <a href="https://tymeinc.com/investors/press-releases/press-release-details/2021/TYME-Granted-U.S.-Patent-Claims-Covering-Use-of-TYME-19-to-Treat-COVID-19-Infections/default.aspx">company announced</a> the US Patent and Trademark Office granted additional patent claims for their product TYME-19-a metabolomic technology directed at treating COVID-19.As an emerging biotechnology company, <keyword id="10701756" type="UNKNOWN" weightage="60" keywordseo="tyme">Tyme</keyword> Technologies usually focuses on developing treatments for advanced cancers through its cancer metabolism-based therapies called CMBTs™.However, when the pandemic struck, the company refocused some of its efforts to developing treatments that might help fight the COVID-19 virus. Now the US patent and Trademark Office has granted Tyme US Patent No. 10,905,698 to do just that.However, the company still has multiple steps to navigate before the treatment will be available to the public. The clinical-stage <keyword id="45082" type="PERSON" weightage="60" keywordseo="biotech">biotech</keyword> firm's TYME-19 metabolomic technology remains an "investigational compound" that is not approved in the US for any disease treatment at this time.Read more: <a href="https://www.businessinsider.com/gamestop-wallstreetbets-reddit-trader-mania-populist-movement-occupy-wall-street-2021-1?utm_source=markets&amp;utm_medium=ingestgest" target="_blank" rel="noopener">The GameStop mania driven by Reddit traders isn't simple market trolling. It's a populist movement threatening to disrupt the financial system to a degree Occupy Wall Street only dreamed of.</a>Still, in preclinical testing, TYME-19 "repeatedly prevented COVID-19 viral replication without attributable cytotoxicity to the treated cells," according to a press release. TYME-19 is an oral synthetic member of the bile acid family. The technology works to limit cellular metabolism, constraining viral replication."We believe that TYME-19 diminishes the ability of COVID-19 to hijack an infected cell," the company wrote in a statement. "TYME intends to initiate the appropriate clinical trials to substantiate the safety and efficacy of TYME-19."Due to its status as a clinical-stage biotech company, Tyme <a href="https://tymeinc.com/investors/press-releases/press-release-details/2020/TYME-Provides-Business-Update-and-Announces-Second-Quarter-Fiscal-2021-Financial-and-Operating-Results/default.aspx">didn't post revenues</a> in 2020, but the company has a strong pipeline of upcoming therapies and plenty of cash to burn for now with $19.4 million in cash and cash equivalents at the end of the September quarter.Tyme traded up 90%, at $3.46 per share, as of 2:49 PM EST on Wednesday.

Tyme Technologies skyrockets 120% after securing new patent claims for Covid-19 infection fighting technology

<div class="KonaFilter image-container display-table float_right"><div><div class="image on-image"></div></div></div>J. Craig Venter, the scientist who led the project to sequence the first human genome, is getting into the elite healthcare business.Venter's company Human Longevity, Inc. (HLI) has announced plans to launch a medical testing service that includes full genome sequencing, medical imaging, and machine learning to provide "the most complete picture of individual health," <a href="http://www.humanlongevity.com/human-longevity-inc-launches-the-health-nucleus-a-comprehensive-and-personalized-health-platform-for-individuals/">the company said a statement</a>.But it won't be cheap - each checkup at the new venture, called Health Nucleus, would cost $25,000 or $50,000 a pop, depending on the number of people being tested and the kind of testing they seek, Venter said, <a href="http://www.xconomy.com/san-diego/2015/10/14/j-craig-venter-debuts-elite-testing-service-via-health-nucleus/">according to Xconomy</a>.The first Health Nucleus is opening in San Diego, at HLI's headquarters, and others are scheduled to open in other US and international cities in 2016.Here are the services it plans to provide:<ul><li>Whole human genome sequencing will give a readout of a person's full set of 6 billion DNA "letter" pairs (most DNA tests cover less than 2% of your genome, according to HLI)</li><li>Microbiome sequencing will measure the combined DNA of the microbes that live in and on the human body</li><li>Metabolome characterization will measure the unique chemical fingerprints of the processes that occur in living cells</li><li>A comprehensive body MRI scan&#xa0;will screen for anything abnormal and provide a baseline picture&#xa0;of health</li><li>Other customized laboratory tests and screenings</li></ul>According to HLI, "An experienced team of clinicians, geneticists and bioinformaticians curate these data and produce an integrated report that can inform clients' care."But some people are skeptical of the testing service's motives. New York Times <keyword id="41551" type="ENTERTAINMENT" weightage="100" keywordseo="science">science</keyword> journalist Carl Zimmer tweeted:<div></div>(A false positive is a test result that incorrectly finds a medical condition that is not actually present.)Venter called the comment&#xa0;"very naive," (though he didn't say why), adding only that "Technology has advanced in the last 10 years."&#xa0;Zimmer and others also pointed out that with all that genetic data, you might want some genetic counseling on what to do with it. For example, if you find out you're at risk of a certain disease - should you seek costly (and possibly unncessary) preventative treatment?In addition, many of Health Nucleus' tests are not FDA-approved, since they haven't yet been tested. According to Xconomy, HLI was able to get around this by operating as a clinical research project subject to basic Institutional Research Board (IRB) protocols.But Venter is optimistic about the venture's future."The Health Nucleus is our opportunity to lead the way to genomic health, enabling individuals and their physicians to pivot towards a more proactive, preventative and predictive healthcare future," he said in a statement.As long as they can afford it, that is. <div class="margin-top"> <h3>NOW WATCH: <a href="http://www.businessinsider.com/how-the-crispr-dna-editing-tool-works-2015-10">Watch science writer Carl Zimmer explain CRISPR in 90 seconds</a></h3> <div> <div> <div class="ooyala-video-player" data-video-autoplay="false" data-video-id="02Z2M0eDoPAy5YuLDPvh7Tg3nC3qY_56" data-player-variable="ooyalapopvideo" id="ooyalaplayer_popvideo" style="width:1280px;height:720px"></div> </div> </div> </div>

You Searched For "metabolomics" and got 4 results

This Start-up Provides Genetic Screening For Newborns, Adults; To Raise Series A Funding In 2-3 Months

Sanghamitra Mandal

Dozens of illnesses across 28 states are now linked to a company's 'microdosing' gummies and chocolate bars

Lauren Edmonds

Tyme Technologies skyrockets 120% after securing new patent claims for Covid-19 infection fighting technology

Will Daniel

A new company plans to offer $25,000 genetic health screenings for the super-rich

Tanya Lewis

Popular Keywords

Buying Guides